Diferelin

Roman name

Diphereline

The composition and the form of

1 orange powder preparation suspension extended release for a / m of the triptorelina 3.75 mg; in a contour acheikova package together with the solvent in the ampoule, one syringe and two needles in paper cartons 1 complekt.1 skin powder preparation for the suspension w / to a 0.1 mg; in a contour acheikova package together with the solvent (in 1 ml ml), in a cardboard bundle seven kits.

Of drugs

Gonadotroponoe. Analogous rilizing gonadotropin hormone. Decreases sensitivity peripheral receptors to the effects of hormone, gonadotropin vswobozdauschego contributes to a decrease in the level of LG and opened, reducing testosterone secretions.

Pharmacokinetics

After the / m of 3.75 mg C_max plasma was 0.32 ± 0.12 ng / ml, and bioavailability in / m introduction once a month-53%.

Indications

Gormonozawisimy cancer prostate cancer, premature puberty, endometriosis, female infertility (stimulating ovulation, the reproduction), mioma uterus, including before surgery.

Pregnancy and lactation

Contraindicated. At the time of treatment should stop breastfeeding.

Contraindications

Hypersensitivity, pregnancy, breast-feeding.

Side-Effects

From the urogenital system : the urine, impotence, a krovanistye or vaginal dryness, giperstimulyatsia ovaries (an increase in the amount of cancer, the pain in the abdomen). From the bones : weakness or paresthesia legs, pain in the bones, Demineralisation Kostei.prochie : headache, hot flashes, fatigue, increased AD pain at the injection.

Specific guidance

In the treatment gormonozawisimogo prostate cancer testosterone levels in the blood should not exceed 1 ng / ml, in the treatment process requires thorough medical surveillance (especially in patients with metastases in the spine or in violation of urination). When treating female infertility need regular biological and clinical monitoring induction ovaries (for the suspicion giperstimulatia to stop injections). Prolonged use of the endometriose and uterine myoma may cause gipogonadotroponuu amenoreu (ovarian function and owulyatsia restored by an average of the 58th day after the last injection).

Dosing and Administration

3.75 mg, in the / m, 0.1 mg, p / K.pri gormonozawisimom cancer prostate cancer : in / m single 3.75 mg every 4 Ned.pri premature sexual maturation : in / m in the one-off dose of 50 µ g / kg every 4 Ned.pri endometriose : the dose of 3.75 mg every 4 weeks. Treatment started in the first five days of menstrual cycle; Treatment duration 4-6 months, refresher courses not Recomenduutxia.pri's barrenness : in / m single 3.75 mg per second day menstrual Zikla.pri uterine myoma : in one dose of 3.75 mg every 4 weeks. Treatment started in the first five days of menstrual cycle; Length of treatment, the operation three months, but in other cases up to six months.

Storage conditions

por.d / in.v / m : When temperature 15-25 ° Cpor.d / in.p / to : When temperature 15-25 ° C

Shelf life

por.d / in.v / m : 2 g.por.d / in.p / to : 1 year

Directory → Antineoplastic funds → Antineoplastic hormonal and hormone antagonists → Diferelin